Valion Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VBIO research report →
Price Chart
About the company
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
- CEO
- Michael R. Cavanaugh
- IPO
- 2021
- Employees
- 52
- HQ
- San Antonio, TX, US
Get TickerSpark's AI analysis on VBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.04M
- P/E
- -0.00
- PEG
- 0.00
- P/S
- -6.63
- P/B
- 0.01
- EV/EBITDA
- -1.05
- Div Yield
- 0.00%
- Gross Margin
- 516.03%
- Op Margin
- 10587.18%
- Net Margin
- 12019.23%
- ROE
- -165.44%
- ROIC
- -55.13%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-7,898,000
- Net Income
- $-8,878,000-57.0%
- EPS
- $-7.84+60.2%
- OCF Growth
- -22.3%
- FCF Growth
- -22.9%
- 52W High
- $67.50
- 52W Low
- $0.47
- 50D MA
- $1.47
- 200D MA
- $12.94
- Beta
- 1.91
- RSI (14)
- 25
- Avg Volume
- 1.78M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tivic said the quarter marked continued transformation toward biopharma, with early progress on entolimod manufacturing and IND transfers, while financials still reflected a small, shrinking consumer business and rising R&D spend.· November 14, 2025
- Transferred two entolimod INDs to Tivic, enabling planned clinical work in neutropenia, lymphocyte exhaustion, and oncology-related applications.
- Completed cell line verification for entolimod, a key step toward larger-batch production and future CGMP/BLA work.
- Consumer health exit continued: the company recorded inventory reserves and asset write-offs and said it does not expect significant additional exit costs.
- VNS optimization study produced surprising results, including possible effects on both sympathetic and parasympathetic activity, prompting a reassessment of the initial commercial focus.
- Cash improved to $3.5 million at quarter-end, supported by financing tranches, while management said there is no debt.
Revenue net of returns was $140,000 in the third quarter of 2025, up from $126,000 a year ago; nine-month revenue was $302,000 versus $600,000 in 2024. Cost of sales was $291,000 in the quarter versus $82,000 last year, mainly due to a $230,000 inventory reserve; gross margin excluding that reserve was 42% versus 35% a year ago. Operating expenses were $2.3 million versus $1.5 million, and net loss was $2.6 million versus $1.4 million. For the first nine months, operating expenses were $5.9 million versus $4.4 million and net loss was $6.0 million versus $4.2 million. Cash and cash equivalents were $3.5 million at 09/30/2025 versus $2.0 million at 12/31/2024, and management said remaining preferred purchase agreement tranches should help fund GMP manufacturing validation for entolimod.
Jennifer Ernst framed the quarter as part of a broader company reset from bioelectronics to biologics centered on the immune system. She emphasized progress on entolimod, including IND transfers, manufacturing readiness, and discussions with BARDA and other government stakeholders about acute radiation syndrome stockpiling. On VNS, she said the optimization data were stronger and more surprising than expected, and that the company is evaluating alternative commercial opportunities because the findings may broaden the program’s potential.
Lisa Wolf said the quarter’s numbers reflect the shift away from consumer devices and toward the biopharmaceutical strategy. She highlighted a $230,000 inventory reserve in cost of goods sold and a $117,000 write-off of ClearUp-related assets, while noting the company does not expect additional significant exit costs. She pointed to $3.5 million in cash and cash equivalents, no debt, and said remaining planned tranches of the preferred purchase agreement should support progress toward GMP manufacturing validation for entolimod.
There was no traditional analyst Q&A in the transcript; the call was a prerecorded update with no external questions. Management’s main implied answers were around why costs rose, why revenue was still small, and whether the company had enough resources: they attributed expense growth to biologics R&D and said the balance sheet, plus financing tranches, should fund near-term manufacturing milestones. On the strategic side, they also signaled that VNS may need a revised commercial strategy after unexpected optimization results.
The positive case is that Tivic says it has materially advanced its new entolimod strategy: IND transfers are complete, cell line verification is done, and the company believes it can move into Phase II for neutropenia and lymphocyte exhaustion based on existing human safety data. Management also sees potential government and BARDA-related demand for entolimod as an ARS stockpile countermeasure, while the VNS data may broaden commercial possibilities rather than narrow them.
The biggest risks are execution and funding: the company acknowledged delays in manufacturing due to financial stress at a contract manufacturer, and it is still early in the shift to biopharma. Revenue remains small and the consumer business is being wound down, with inventory reserves and asset write-offs weighing on results. The VNS program also lost some of its original commercial clarity because management said the new findings may force a reassessment of its initial focus.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 2.16M
- Float Shares
- 2.15M
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 22, 26 | Zikria Dean | other | 50,000 |
| Sep 18, 26 | Wolf Lisa G | other | 4 |
| Sep 18, 26 | Wolf Lisa G | other | 2 |
| Sep 18, 26 | Wolf Lisa G | other | 4 |
| Aug 27, 26 | Malbin Jared David | other | 0 |
| Aug 27, 26 | Jensen Thomas | other | 0 |
| Jun 18, 26 | Wolf Lisa G | other | 92 |
| Jun 18, 26 | Wolf Lisa G | other | 92 |
| May 18, 26 | Handley Michael K | other | 2,206 |
| May 18, 26 | Handley Michael K | other | 2,206 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VBIO coverage
Recent articles, reports, and earnings notes.
No research on VBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VBIO report →Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
accessnewswire.com · Oct 21
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
accessnewswire.com · Oct 15
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
accessnewswire.com · Oct 14
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
accessnewswire.com · Oct 9
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
accessnewswire.com · Oct 5
Reviewing I-Mab (NASDAQ:NBP) & Valion Bio, Inc. Common Stock (NASDAQ:VBIO)
defenseworld.net · Oct 1
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
accessnewswire.com · Sep 30
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
accessnewswire.com · Sep 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.